JP6271407B2 - 細胞評価統合方法 - Google Patents
細胞評価統合方法 Download PDFInfo
- Publication number
- JP6271407B2 JP6271407B2 JP2014254812A JP2014254812A JP6271407B2 JP 6271407 B2 JP6271407 B2 JP 6271407B2 JP 2014254812 A JP2014254812 A JP 2014254812A JP 2014254812 A JP2014254812 A JP 2014254812A JP 6271407 B2 JP6271407 B2 JP 6271407B2
- Authority
- JP
- Japan
- Prior art keywords
- cell
- evaluation
- medium
- integration method
- cell group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011156 evaluation Methods 0.000 title claims description 93
- 238000000034 method Methods 0.000 title claims description 49
- 230000010354 integration Effects 0.000 title claims description 38
- 239000000203 mixture Substances 0.000 claims description 38
- 239000000126 substance Substances 0.000 claims description 33
- 230000008859 change Effects 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 23
- 238000001228 spectrum Methods 0.000 claims description 13
- 230000002123 temporal effect Effects 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 3
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 220
- 210000000130 stem cell Anatomy 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QUTFFEUUGHUPQC-ILWYWAAHSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC1=CC=C([N+]([O-])=O)C2=NON=C12 QUTFFEUUGHUPQC-ILWYWAAHSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- -1 7-Nitro-2,1,3-benzoxadiazol-4-yl Chemical group 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
11 細胞群
11 分割細胞群
11 細胞群
12 媒質
20 小型容器
21 分割細胞群
22 媒質
Claims (28)
- 複数の細胞からなる細胞群を分割して、複数の細胞からなる分割細胞群を複数作成し、
該作成した分割細胞群の単位で細胞の性質の評価を行い、
該各分割細胞群の評価結果に基づいて、複数の前記分割細胞群を分類し、
同じ分類に属する前記分割細胞群を統合して統合細胞群を作成することを特徴とする細胞評価統合方法。 - 前記分割細胞群とともに容器に収容された媒質の組成に基づいて前記評価を行う請求項1記載の細胞評価統合方法。
- 前記媒質の組成の時間変化に基づいて前記評価を行う請求項2記載の細胞評価統合方法。
- 前記分割細胞群とともに容器に収容された媒質中の糖、アミノ酸、ペプチド、タンパク質および核酸のうちの少なくとも1つの量の時間変化に基づいて前記評価を行う請求項1記載の細胞評価統合方法。
- 前記分割細胞群とともに容器に収容された媒質中の指示薬の色に基づいて前記評価を行う請求項1記載の細胞評価統合方法。
- 前記媒質中の指示薬の色の時間変化に基づいて前記評価を行う請求項5記載の細胞評価統合方法。
- 前記指示薬の色が、前記媒質の性質、前記媒質の組成または前記媒質中の物質の量に応じて決まる請求項5または6記載の細胞評価統合方法。
- 前記指示薬の色の時間変化が、前記媒質の性質、前記媒質の組成または前記媒質中の物質の量に応じて決まる請求項6記載の細胞評価統合方法。
- 前記指示薬としてフェノールレッドを用いる請求項5から8いずれか1項記載の細胞評価統合方法。
- 前記分割細胞群とともに容器に収容された媒質から発せられた光の量に基づいて前記評価を行う請求項1記載の細胞評価統合方法。
- 前記媒質から発せられた光の量の時間変化に基づいて前記評価を行う請求項10記載の細胞評価統合方法。
- 前記媒質から発せられる光の量が、前記媒質の組成または前記媒質中の物質の量に応じて決まる請求項10または11記載の細胞評価統合方法。
- 前記分割細胞群から発せられた光の量に基づいて前記評価を行う請求項1記載の細胞評価統合方法。
- 前記分割細胞群から発せられた光の量の時間変化に基づいて前記評価を行う請求項13記載の細胞評価統合方法。
- 前記分割細胞群から発せられる光の量が、前記細胞の組成または前記細胞中の物質の量に応じて決まる請求項13または14記載の細胞評価統合方法。
- 前記分割細胞群とともに容器に収容された媒質から発せられた光のスペクトルに基づいて前記評価を行う請求項1記載の細胞評価統合方法。
- 前記媒質から発せられた光のスペクトルの時間変化に基づいて前記評価を行う請求項16記載の細胞評価統合方法。
- 前記媒質から発せられる光のスペクトルが、前記媒質の組成または前記媒質中の物質の量に応じて決まる請求項16または17記載の細胞評価統合方法。
- 前記分割細胞群から発せられた光のスペクトルに基づいて前記評価を行う請求項1記載の細胞評価統合方法。
- 前記分割細胞群から発せられた光のスペクトルの時間変化に基づいて前記評価を行う請求項19記載の細胞評価統合方法。
- 前記分割細胞群から発せられる光のスペクトルが、前記細胞の組成または前記細胞中の物質の量に応じて決まる請求項19または20記載の細胞評価統合方法。
- 前記光が、蛍光または化学発光である請求項16から21いずれか1項記載の細胞評価統合方法。
- 前記分割細胞群とともに容器に収容された媒質から発せられた蛍光の寿命に基づいて前記評価を行う請求項1記載の細胞評価統合方法。
- 前記分割細胞群から発せられた蛍光の寿命に基づいて前記評価を行う請求項1記載の細胞評価統合方法。
- 前記分割細胞群に対して刺激を加えた後に前記評価を行う請求項1から24いずれか1項記載の細胞評価統合方法。
- 前記分割細胞群に対する刺激が、物質の添加、物質の除去、温度の変化および電磁波の照射のうちの少なくとも1つである請求項25記載の細胞評価統合方法。
- 前記評価として、がんらしさを評価する請求項1から26いずれか1項記載の細胞評価統合方法。
- 前記細胞の増殖速度に基づいて、前記細胞群の分割数を決定する請求項1から27いずれか1項記載の細胞評価統合方法。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014254812A JP6271407B2 (ja) | 2014-12-17 | 2014-12-17 | 細胞評価統合方法 |
PCT/JP2015/083160 WO2016098551A1 (ja) | 2014-12-17 | 2015-11-26 | 細胞評価統合方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014254812A JP6271407B2 (ja) | 2014-12-17 | 2014-12-17 | 細胞評価統合方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016111982A JP2016111982A (ja) | 2016-06-23 |
JP6271407B2 true JP6271407B2 (ja) | 2018-01-31 |
Family
ID=56126448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014254812A Active JP6271407B2 (ja) | 2014-12-17 | 2014-12-17 | 細胞評価統合方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6271407B2 (ja) |
WO (1) | WO2016098551A1 (ja) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0658369B2 (ja) * | 1985-08-09 | 1994-08-03 | 國衛 中村 | 腫瘍に由来するpH緩衝能の検出方法 |
US8815517B2 (en) * | 1999-12-28 | 2014-08-26 | Ribonomics, Inc. | Methods for identifying functionally related genes and drug targets |
JP2001330604A (ja) * | 2000-05-18 | 2001-11-30 | Matsushita Electric Ind Co Ltd | 薬物候補物質の検出システムおよび検出方法 |
US11739366B2 (en) * | 2010-07-23 | 2023-08-29 | Astellas Institute For Regenerative Medicine | Methods for detection of rare subpopulations of cells and highly purified compositions of cells |
JP6327565B2 (ja) * | 2012-10-03 | 2018-05-23 | 国立大学法人弘前大学 | クマリン誘導体が結合した蛍光標識糖誘導体を用いた細胞イメージング方法及びイメージング剤 |
-
2014
- 2014-12-17 JP JP2014254812A patent/JP6271407B2/ja active Active
-
2015
- 2015-11-26 WO PCT/JP2015/083160 patent/WO2016098551A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2016111982A (ja) | 2016-06-23 |
WO2016098551A1 (ja) | 2016-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fenech et al. | HUMN project initiative and review of validation, quality control and prospects for further development of automated micronucleus assays using image cytometry systems | |
Muñoz et al. | Channelrhodopsin-assisted patching: in vivo recording of genetically and morphologically identified neurons throughout the brain | |
CN105954246B (zh) | 一种在人的生物液体样本中检测游离的稀有肿瘤细胞的方法和试剂盒 | |
Chang et al. | Emerging applications of flow cytometry in solid tumor biology | |
CN102341505A (zh) | 细胞的遗传学分析 | |
JP5289064B2 (ja) | 生物学的サンプルの画像化および修飾のための装置および方法 | |
US20050233309A1 (en) | Kinetic process for the detection, diagnosis, processing, and monitoring of clonal cell populations | |
CN1324146C (zh) | BCR-ABL融合基因(P210bcr/abl)mRNA荧光定量RT-PCR检测试剂盒 | |
Qi et al. | A SERS and fluorescence dual-channel microfluidic droplet platform for exploring telomerase activity at the single-cell level | |
JP4977325B2 (ja) | 精度管理用疑似組織及びそれを用いた精度管理方法 | |
WO2018124210A1 (ja) | 環状心筋細胞塊 | |
JP6271407B2 (ja) | 細胞評価統合方法 | |
CN108486221A (zh) | 检测端粒长度的方法 | |
JP2006340684A (ja) | 微生物の計測方法 | |
KR101333665B1 (ko) | 자기공명분광법을 이용한 세포증식 및 분화 상태의 비침습적 측정방법, 이에 이용되는 자기공명분광용 세포 증식 및 분화마커 | |
Pham et al. | Label free metabolic imaging to enhance the efficacy of Chimeric Antigen Receptor T cell therapy | |
KR20230062568A (ko) | 세포 배양물의 자동화된 분석 | |
Barteneva et al. | Heterogeneity of metazoan cells and beyond: To integrative analysis of cellular populations at single-cell level | |
Chomik et al. | Impact of lymphocyte culture media on the number of metaphases and chromosome band resolution | |
WO2023136308A1 (ja) | ラマン散乱を用いた心筋細胞の評価方法 | |
RU2619640C1 (ru) | Способ идентификации микроводорослей | |
Babatunde et al. | Naive primary neutrophils play a dual role in the tumor microenvironment | |
Atha et al. | Standards for Quantitative Measurement of DNA Damage in Mammalian Cells | |
EP4092132A1 (en) | Sample for evaluating performance of genetic testing apparatus, method for preparing said sample, and device for evaluating performance, method for evaluating performance, program for evaluating performance, and apparatus for evaluating performance of genetic testing apparatus | |
Clarke et al. | Toxicity testing using hematopoietic stem cell assays |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170308 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20170523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170908 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170908 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171205 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171227 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6271407 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |